performed on advanced melanoma patients showed that while both anti-CTLA4 and anti-PD1 treatments were associated with higher PFS rates when each treatment was compared to control, an indirect comparison of these two agents showed superior 6-month PFS of 28.5% versus 17.7% and ORR of 29.6% versus 17.7% in anti-PD1 compared to anti-CTLA4 treatment.85 The gene discussed is CTLA4; the disease is melanoma.